Abstract
Combining voriconazole and flucloxacillin is indicated in patient cohorts experiencing both invasive aspergillosis and Gram-positive infections (e.g., patients with chronic granulomatous disease or postinfluenza pulmonary aspergillosis). We report a highly relevant interaction between voriconazole and flucloxacillin, resulting in subtherapeutic plasma voriconazole concentrations in more than 50% of patients, that poses a severe threat if not managed properly.
Original language | English |
---|---|
Article number | e00915-17 |
Number of pages | 5 |
Journal | Antimicrobial Agents and Chemotherapy |
Volume | 61 |
Issue number | 9 |
DOIs | |
Publication status | Published - Sept 2017 |
Keywords
- aspergillosis
- drug interactions
- exposure
- influenza
- pharmacokinetics
- HUMAN LIVER-MICROSOMES
- PHARMACOKINETIC INTERACTIONS
- CLINICAL-RELEVANCE
- METABOLISM
- CYP2C19